Viroids offer new gene-silencing possibilities
12 September, 2003 by Graeme O'NeillThey're not life as we know it, not even life at all. A viroid is just a naked, sub-microscopic loop of single-stranded RNA -- a virus in the buff. But despite their simplicity, viroids possess a primeval weapon that can devastate crops- a weapon that of recent and great interest to molecular biologists.
Starpharma losses down, revenues up
12 September, 2003 by Melissa TrudingerStarpharma's (ASX:SPL) 2002-03 revenues jumped 11 per cent to AUD$1.5 million and its operating loss fell to $7.7 million, the company has announced.
AGT revenues up, losses down on last year
11 September, 2003 by Melissa TrudingerAGT Biosciences (ASX:AGT) has posted its annual financial results, showing an 11 per cent increase in revenues to $AUD5.2 million, and a loss of $1.9 million down 74.7 per cent from the previous year's loss of $7.5 million.
GTG suing Applera, Covance over patent infringement
11 September, 2003 by Melissa TrudingerMelbourne based Genetic Technologies (ASX:GTG) is taking on three of the big guns in the biotechnology industry.
Xcell to speed up US push
10 September, 2003 by Melissa TrudingerXcell Diagnostics (ASX:XEL) will accelerate plans to file for FDA approval of its microDERM video dermatoscope system, following a positive review of its programs by senior management and expert advisors.
Biota aims to raise $13m in share purchase plan
10 September, 2003 by Melissa TrudingerBiota (ASX:BTA) is offering shareholders a chance to buy up to AUD$5000 worth of shares at a 10 per cent discount to the market price, the company announced today.
Genesis to launch Phase II eczema trial in UK
10 September, 2003 by Graeme O'NeillAuckland biopharma Genesis Research and Development Corporation (NSX/ASX:GEN) is to begin a Phase II clinical trial of its AVAC therapy for paediatric atopic dermatitis, or childhood eczema.
GTG promises more licensing revenue in coming year
10 September, 2003 by Melissa TrudingerMelbourne biotech Genetic Technologies (ASX:GTG) has released its financial results for 2002-03 financial year, showing a 29 per cent revenue drop to AUD$9.26 million and a net loss of $4.16 million, an improvement over last year's $8.8 million loss.
Starpharma raises $6.9m
10 September, 2003 by Melissa TrudingerPooled investment firm and nanotech specialist Starpharma (ASX:SPL) has raised AUD$6.9 million in an oversubscribed placement to institutional and sophisticated investors.
Prana touts development as possible Alzheimer's therapy
10 September, 2003 by Graeme O'NeillMelbourne-based biomedical company Prana Biotechnology (ASX:PBT) has announced it has developed a set of assays for high-throughput testing of molecules with therapeutic potential for Alzheimer's disease.
Peplin blames R&D expenditure for loss
09 September, 2003 by Graeme O'NeillBrisbane cancer-drug developer Peplin Biotech (ASX:PEP) has reported a consolidated loss of AUD$3.7 million for the 12 months to June 30, largely attributable to a big increase in research expenditure on its lead compound, PEP005.
GTG acquires sports gene test rights from Sydney Uni
08 September, 2003 by Melissa TrudingerMelbourne genetic testing company Genetic Technologies (ASX:GTG) has acquired the exclusive worldwide rights to commercialise a test for a gene underlying athletics and sports performance from the University of Sydney.
EpiTan loss doesn't detract from solid year
08 September, 2003 by Melissa TrudingerMelbourne biotech company EpiTan (ASX:EPT) has posted a loss of AUD$4 million for the 2002-2003 financial year, primarily due to the expenses of running Phase II clinical trials on its lead drug candidate Melanotan.
Prana raises $5m from institutional investors
08 September, 2003 by Melissa TrudingerJoining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.
Xcell collaborators earn $1m NIH grant
05 September, 2003 by Melissa TrudingerCollaborators of Perth devices company Xcell Diagnostics (ASX:XEL) have received a US NIH grant worth more than AUD$1 million (US$702,000) to perform clinical studies on Xcell's Funhaler paediatric asthma spacer device.
